TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
Hansa Biopharma AB
Closing information (x1000 NOK)
Closing information | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Turnover |
146,167
|
33,039
|
6,388 |
Financial expenses |
46,008
|
1,189
|
269 |
Earnings before taxes |
-576,987
|
-534,549
|
-440,928 |
EBITDA |
-556,753
|
-533,425
|
-434,902 |
Total assets |
1,596,139
|
987,713
|
1,502,780 |
Current assets |
1,517,910
|
918,993
|
1,459,714 |
Current liabilities |
250,396
|
166,977
|
119,639 |
Equity capital |
570,301
|
738,802
|
1,301,251 |
- share capital |
52,057
|
45,187
|
43,421 |
Employees (average) |
144
|
116
|
82 |
Financial ratios
Fiscal year | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Solvency |
35.7%
|
74.8%
|
86.6% |
Turnover per employee |
1,015
|
285
|
78 |
Profit as a percentage of turnover |
-394.7%
|
-1617.9%
|
-6902.4% |
Return on assets (ROA) |
-33.3%
|
-54.0%
|
-29.3% |
Current ratio |
606.2%
|
550.4%
|
1220.1% |
Return on equity (ROE) |
-101.2%
|
-72.4%
|
-33.9% |
Change turnover |
114,122
|
27,092
|
2,864 |
Change turnover % |
356%
|
456%
|
81% |
Chg. No. of employees |
28
|
34
|
19 |
Chg. No. of employees % |
24%
|
41%
|
30% |
Total value of public sale
Fiscal year | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Total value of public sale |
0
![]() |
0
![]() |
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.